AMGN
Price
$468.11Alerts
Change
+$2.88 (+0.62%)
Updated
Nov 11 closing price
Capitalization
248.92B
89 days until earnings call
Intraday BUY SELL Signals
GRFS
Price
$8.84Alerts
Change
+$0.08 (+0.91%)
Updated
Nov 11 closing price
Capitalization
5.74B
112 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMGN vs GRFS

AMGN vs GRFS Comparison Chart in %
View a ticker or compare two or three
VS
AMGN vs. GRFS commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and GRFS is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AMGN with price predictions
Nov 11, 2026

AMGN in upward trend: 10-day moving average moved above 50-day moving average on October 16, 2026

The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMGN as a result. In 43 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.

AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 194 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.

The Aroon Indicator entered an Uptrend today. In 151 of 272 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.

Bearish Trend Analysis

The 10-day RSI Indicator for AMGN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 28 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 61%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 67 cases where AMGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 48%.

The Moving Average Convergence Divergence Histogram (MACD) for AMGN turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 25 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 51%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.

AMGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to good earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.297) is normal, around the industry mean (-1.421). P/E Ratio (28.386) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.022) settles around the average of (0.038) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).

A.I.Advisor
a Summary for GRFS with price predictions
Nov 11, 2026

Momentum Indicator for GRFS turns positive, indicating new upward trend

GRFS saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In 64 of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

GRFS moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for GRFS crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.

Following a +1.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where GRFS advanced for three days, in 195 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.

The Aroon Indicator entered an Uptrend today. In 144 of 210 cases where GRFS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRFS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

GRFS broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.034) is normal, around the industry mean (-1.421). P/E Ratio (12.773) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (0.189) is also within normal values, averaging (5.738). Dividend Yield (0.042) settles around the average of (0.038) among similar stocks. GRFS's P/S Ratio (0.592) is slightly lower than the industry average of (4.033).

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating fairly steady price growth. GRFS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.

FUNDAMENTALS RATINGS
AMGN vs GRFS: Fundamental Ratings
AMGN
GRFS
OUTLOOK RATING
1..100
4046
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
16
Undervalued
PROFIT vs RISK RATING
1..100
3100
SMR RATING
1..100
1576
PRICE GROWTH RATING
1..100
941
P/E GROWTH RATING
1..100
3355
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GRFS's Valuation (16) in the Pharmaceuticals Major industry is somewhat better than the same rating for AMGN (79) in the Biotechnology industry. This means that GRFS’s stock grew somewhat faster than AMGN’s over the last 12 months.

AMGN's Profit vs Risk Rating (3) in the Biotechnology industry is significantly better than the same rating for GRFS (100) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than GRFS’s over the last 12 months.

AMGN's SMR Rating (15) in the Biotechnology industry is somewhat better than the same rating for GRFS (76) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than GRFS’s over the last 12 months.

AMGN's Price Growth Rating (9) in the Biotechnology industry is in the same range as GRFS (41) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to GRFS’s over the last 12 months.

AMGN's P/E Growth Rating (33) in the Biotechnology industry is in the same range as GRFS (55) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to GRFS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMGNGRFS
RSI
ODDS (%)
Bearish Trend 1 day ago
61%
Bearish Trend 1 day ago
74%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
48%
Bearish Trend 1 day ago
73%
Momentum
ODDS (%)
Bullish Trend 1 day ago
59%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bearish Trend 1 day ago
51%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
49%
Bullish Trend 1 day ago
71%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
60%
Bullish Trend 1 day ago
71%
Advances
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 1 day ago
69%
Declines
ODDS (%)
Bearish Trend 9 days ago
47%
Bearish Trend 6 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
55%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
56%
Bullish Trend 1 day ago
69%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (AMGN: $468.11 vs. GRFS: $8.84)
Brand notoriety: AMGN: Notable vs. GRFS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMGN: 57% vs. GRFS: 137%
Market capitalization -- AMGN: $248.92B vs. GRFS: $5.74B
AMGN [@Pharmaceuticals: Major] is valued at $248.92B. GRFS’s [@Pharmaceuticals: Major] market capitalization is $5.74B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $4.8K to $1.21T. The average market capitalization across the [@Pharmaceuticals: Major] industry is $215.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMGN’s FA Score shows that 4 FA rating(s) are green while GRFS’s FA Score has 1 green FA rating(s).

  • AMGN’s FA Score: 4 green, 1 red.
  • GRFS’s FA Score: 1 green, 4 red.
According to our system of comparison, AMGN is a better buy in the long-term than GRFS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMGN’s TA Score shows that 5 TA indicator(s) are bullish while GRFS’s TA Score has 5 bullish TA indicator(s).

  • AMGN’s TA Score: 5 bullish, 5 bearish.
  • GRFS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both AMGN and GRFS are a good buy in the short-term.

Price Growth

AMGN (@Pharmaceuticals: Major) experienced а -2.17% price change this week, while GRFS (@Pharmaceuticals: Major) price change was +2.67% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.46%. For the same industry, the average monthly price growth was +2.44%, and the average quarterly price growth was +7.11%.

Reported Earning Dates

AMGN is expected to report earnings on Feb 09, 2027.

GRFS is expected to report earnings on Mar 04, 2027.

Industries' Descriptions

@Pharmaceuticals: Major (-1.46% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

View a ticker or compare two or three
Interact to see
Advertisement

AMGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with PFE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMGN
1D Price
Change %
AMGN100%
+0.62%
PFE - AMGN
51%
Loosely correlated
+0.31%
GILD - AMGN
48%
Loosely correlated
-0.67%
ABBV - AMGN
48%
Loosely correlated
+0.37%
BIIB - AMGN
47%
Loosely correlated
+0.06%
MRK - AMGN
47%
Loosely correlated
-0.59%
More

GRFS and

Correlation & Price change

A.I.dvisor tells us that GRFS and SNY have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GRFS and SNY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
+0.91%
SNY - GRFS
32%
Poorly correlated
+0.41%
GILD - GRFS
30%
Poorly correlated
-0.67%
GSK - GRFS
30%
Poorly correlated
-1.23%
AMGN - GRFS
30%
Poorly correlated
+0.62%
BMY - GRFS
29%
Poorly correlated
+0.18%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TSLG5.210.28
+5.68%
Leverage Shares 2X Long TSLA Daily ETF (TSLG)
VTHR335.294.13
+1.25%
Vanguard Russell 3000 ETF (VTHR)
SEPU31.490.29
+0.93%
AllianzIM U.S. Equity Buffer15 Uncapped Sep ETF (SEPU)
DPG13.960.11
+0.79%
Duff & Phelps Utility and Infrastructure Fund
GGRW36.13-0.18
-0.51%
Gabelli Growth Innovators ETF (GGRW)